Neuralstem Appoints CEO
This article was originally published in Scrip
Executive Summary
Neuralstem, a company focused on therapies for the central nervous system, has appointed Richard J. Daly president, CEO and a member of the company's board of directors. Daly has more than 25 years' experience and will succeed Richard Garr, J.D., who was president and CEO since co-founding Neuralstem. Recently, Dale was managing director of Ravine Rock Partners, LLC. and interim chief commercial officer at Catalyst Pharma until Sept. 2015. He also led the turnaround initiatives of the Bristol-Myers Squibb and AstraZeneca plc's diabetes alliance whilst serving as president of the US diabetes subsidiary from 2013 through the AstraZeneca integration completion in 2014.